Fluoxymesterone appeared in a period that is often called the "golden age" of steroid chemistry. In the 1950s, pharmaceutical companies were racing to create new hormone molecules, and one of the most interesting areas was the fluorination of steroids. The editors trace the path of halotestin from the laboratory of the Upjohn company to oncology clinics and gyms - and explain why its medical use has almost disappeared today.
Steroid Chemistry in the 1950s: Context
Testosterone was isolated and synthesized in 1935, and within a few years the first derivatives appeared. One of the early discoveries was methyltestosterone: the methyl group at position 17α allowed the hormone to act when taken orally. The price of this convenience, as it turned out later, was toxicity for the liver.
In the post-war years, corticosteroids became the focus of attention. After cortisone showed impressive results in rheumatoid arthritis, companies invested enormous resources in the synthesis of new hormones. Chemists have learned to purposefully change individual atoms of the steroid skeleton and observe how biological activity changes.
An important milestone was the discovery of Fried and Sabo (1954): the introduction of a fluorine atom into the 9α position of cortisol dramatically increased its activity. This is how fludrocortisone appeared, a drug that is still used in medicine. This discovery inspired chemists to try the same trick with androgens.
At the same time, the pharmaceutical industry was looking for "anabolic" steroids - molecules that would retain the ability to increase protein mass, but cause less androgenic effects. This search continued for decades, and fluoxymesterone turned out to be its unexpected byproduct: a powerful, but far from "soft" androgen.
Synthesis of fluoxymesterone at Upjohn
Fluoxymesteron was synthesized by a group of chemists of the Upjohn company (USA); the results were published by Herr, Hogg and Levin in 1956. The molecule combined three modifications: 17α-methyl for oral use, 9α-fluoro and 11β-hydroxyl, which came from experience with corticosteroids.
The very next year, in 1957, the drug appeared on the market under the trade name Halotestin. The name reflected the presence of halogen (fluorine) in the molecule. Later, other trade names appeared in different countries, and in the USA the product was also released as a generic.
Pharmacological studies on animals showed high androgenic and anabolic activity of the new compound, which exceeded the indicators of methyltestosterone. That is why fluoxymesterone has been positioned as an effective oral androgen for replacement therapy and other indications.
Medical indications
The official indications of fluoxymesterone reflected the idea of androgens in the middle of the 20th century. In men, it was prescribed for primary and secondary hypogonadism as replacement therapy. The instructions provided for doses from 5 to 20 mg per day, depending on the clinical situation.
The second indication was delayed puberty in boys. Here, doctors had to be especially careful: androgens accelerate the closure of bone growth zones, so the instructions required monitoring bone age with x-rays every 6 months.
The third, and perhaps most significant, indication is the palliative treatment of androgen-sensitive advanced breast cancer in women. In this situation, higher doses were used - up to 40 mg per day in several doses. In the 1980s and 1990s, the combination of fluoxymesterone and tamoxifen was also studied.
Some sources also mention the use of androgens for certain anemias, but other drugs were more often used for this. Below is a summary of indications based on official labeling data.
| Testimony | Patients | Key caveats |
|---|---|---|
| Hypogonadism | Men with primary or secondary deficiency | Control of the liver, hematocrit |
| Delayed puberty | Teenage boys | X-ray of bone age every 6 months |
| Breast cancer | Women with advanced hormone-sensitive cancer | Virilization, hypercalcemia |
Fluoxymesterone in sports
In the sports environment, fluoxymesterone gained popularity among representatives of strength disciplines - powerlifters, boxers, fighters - for whom it was important to increase strength without noticeable weight gain. According to unofficial evidence, athletes appreciated it for "aggressiveness" in training, although there is no scientific confirmation of such a specific effect.
Since the 1970s, anabolic steroids have been gradually banned in sports: in 1974, the IOC included them in the list of prohibited substances, and with the improvement of gas chromatography and mass spectrometry methods, it became possible to detect synthetic androgens and their metabolites in urine.
Currently, fluoxymesterone is included in the Prohibited List of WADA in category S1 — anabolic agents. For anti-doping control laboratories, it is a known substance with described metabolites.
The history of sports use shows a typical picture: the reputation in the hall was formed on the basis of subjective impressions, while the risks - for the liver, lipids, hormonal system - were known from medical practice, but often ignored.
Why the drug left the scene
Over time, the place of fluoxymesterone in medicine has declined for several reasons. For men's replacement therapy, there are forms of testosterone — injectable esters, patches, gels — that provide the physiological hormone without 17α-alkylation and the hepatotoxicity associated with it.
In the treatment of breast cancer, androgens have replaced agents with a better ratio of effectiveness and tolerability: anti-estrogens, and later aromatase inhibitors. Virilization, inevitable with high doses of androgens, became unacceptable when alternatives appeared.
Data on liver complications of 17α-alkylated androgens — cholestasis, peliosis, liver tumors — were also accumulated (Søe et al., 1992). For the drug, which has safer substitutes, such risks became a decisive argument.
- the emergence of safer forms of testosterone for replacement therapy;
- development of more effective hormonal therapy for breast cancer;
- accumulation of data on hepatotoxicity and effect on lipids;
- limited commercial interest in the old drug.
As a result, the Halotestin brand name was discontinued in the US, and fluoxymesterone worldwide availability was significantly reduced. However, the molecule itself has remained in the history of pharmacology as an example of how an approach that was successful for corticosteroids gave a completely different result in the world of androgens.
Editorial conclusion
Fluoxymesterone is a child of the era of active experimentation with the steroid molecule. The idea of 9α-fluorination came from the chemistry of corticosteroids and produced an extremely potent oral androgen.
Medical indications—hypogonadism, delayed puberty, breast cancer—over time shifted to safer and more effective remedies. Today, the drug has mostly historical significance in medicine.
The story of halotestin well illustrates the general rule: the potency of a molecule does not mean its value to the patient if the risks outweigh the risks.
We also advise you to familiarize yourself with our materials about the side effects of fluoxymesterone, about the risks for women and about the myths surrounding this drug.
References
- Herr ME, Hogg JA, Levin RH. Synthesis of potent oral anabolic-androgenic steroids. J Am Chem Soc. 1956;78.
- Fried J, Sabo EF. 9α-Fluoro derivatives of cortisone and hydrocortisone. J Am Chem Soc. 1954;76.
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502â521.
- Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4â13.
- Søe KL, Søe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver. 1992;12(2):73â79.
- Androxy (fluoxymesterone tablets, USP). Prescribing information. Upsher-Smith Laboratories.
- World Anti-Doping Agency. The World Anti-Doping Code: International Standard — Prohibited List. Montreal: WADA; updated every year.
